Scilex Holding Company (SCLX) Stock

Scilex Holding Company, a dynamic biopharmaceutical firm, specializes in the development and commercialization of innovative non-opioid pain management solutions. Central to its portfolio is ZTlido 1.8%, an advanced prescription lidocaine topical product designed specifically for the relief of neuropathic pain associated with post-herpetic neuralgia, a condition stemming from post-shingles nerve damage.

In addition to ZTlido, Scilex Holding Company is advancing several pipeline candidates aimed at addressing various pain indications. SP-102, a viscous gel formulation of corticosteroid for epidural injections, is currently undergoing Phase III clinical trials targeting lumbosacral radicular pain. The company is also progressing SP-103, which is in Phase II clinical trials for the treatment of low back pain, and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trials targeting fibromyalgia.

Headquartered in Palo Alto, California, Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc., leveraging synergies and resources within the broader organization to advance its innovative pipeline and enhance patient outcomes. The company's commitment to pioneering non-opioid pain management underscores its dedication to addressing the complex challenges of acute and chronic pain conditions with safe and effective therapeutic options.

With a strong focus on research and development, Scilex Holding Company continues to expand its capabilities and scientific understanding, positioning itself at the forefront of biopharmaceutical innovation in pain management. Through strategic partnerships and ongoing clinical advancements, the company aims to bring transformative treatments to patients in need worldwide.